Skip to main content
. 2020 May 5;9(5):44. doi: 10.1038/s41389-020-0228-x

Fig. 2. HAT1-knockout-mediated resistance leads to the long-term survival of melanoma cells treated with BRAF inhibitor.

Fig. 2

a Immunoblotting for the indicated proteins in A375 and SKMEL-28 HAT1-knockout (HAT1-KO) cells. b Clonogenic assay results for A375 and SKMEL-28 cells, expressing non-targeting (NT) or HAT1 sgRNAs, in the presence of vemurafenib (3 μM) (left). Colony number for the data are shown (right). c Clonogenic assay results for A375 and SKMEL-28 cells, expressing NT or HAT1 sgRNAs, in the presence of dabrafenib (100 nM) (left). Colony number for the data presented (right). Data are presented as the mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, calculated using Student’s t test.